Y-4 Tablets with Pregabalin and Riluzole for Healthy Participants

FL
Overseen ByFrank Lee
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

The primary goal of this clinical trial is to compare pharmacokinetic characteristics of Y-4 tablets with pregabalin capsules and riluzole tablets in the US healthy adult participants after single oral administration under fasted condition.

The secondary goal of the trial is to evaluate the safety and tolerability of Y-4 tablets, pregabalin capsules and riluzole tablets in the US healthy adult participants.

Are You a Good Fit for This Trial?

This trial is for healthy adults in the U.S. who do not have any major health problems. Participants should not be taking other medications or have conditions that could affect drug absorption or safety.

Inclusion Criteria

I can understand the study and sign a consent form.
During screening, serum creatinine within normal range or creatinine clearance (CLcr) ≥ 80 mL/min (female CLcr × 0.85)
My weight and BMI are within the required range for my gender.
See 1 more

Exclusion Criteria

Special dietary requirements preventing adherence to unified diet
I am not pregnant, breastfeeding, or recently had unprotected sex.
Consumption of diet rich in grapefruit, pitaya, mango, or cranberry within 14 days prior to screening
See 21 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

1-2 weeks

Treatment Period 1

Participants receive a single oral administration of Y-4 tablet in a fasting state

1 day
1 visit (in-person)

Washout Period 1

7-day washout period between treatments

1 week

Treatment Period 2

Participants receive a single oral administration of pregabalin capsule in a fasting state

1 day
1 visit (in-person)

Washout Period 2

7-day washout period between treatments

1 week

Treatment Period 3

Participants receive a single oral administration of riluzole tablet in a fasting state

1 day
1 visit (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

1 week
1 visit (in-person)

What Are the Treatments Tested in This Trial?

Trial Overview

The study compares how the body processes a new tablet called Y-4 with two existing drugs, pregabalin and riluzole, after a single dose taken on an empty stomach. The trial also checks if these medicines are safe and well-tolerated.

How Is the Trial Designed?

3

Treatment groups

Experimental Treatment

Group I: Y-4 tablesExperimental Treatment1 Intervention
Group II: Riluzole tabletExperimental Treatment1 Intervention
Group III: Pregabalin capsuleExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Neurodawn Pharmaceutical Co., Ltd.

Lead Sponsor

Trials
7
Recruited
3,500+